KRAS and pancreatic neoplasm: From the dose–response results (Figure 2), we selected two of the most efficient PPRHs for each gene, G4-C and I1-T for MYC-targeting PPRHs and PR-C and PPRH 2 for KRAS-targeting PPRHs; these PPRHs were also the most effective against the pancreatic cancer cell line, AsPc-1 [50,51].